|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HMGCR |
Gene summary for HMGCR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HMGCR | Gene ID | 3156 |
| Gene name | 3-hydroxy-3-methylglutaryl-CoA reductase | |
| Gene Alias | LDLCQ3 | |
| Cytomap | 5q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024RAP2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3156 | HMGCR | HCC1_Meng | Human | Liver | HCC | 1.39e-33 | 2.06e-02 | 0.0246 |
| 3156 | HMGCR | HCC2_Meng | Human | Liver | HCC | 5.86e-06 | -2.25e-02 | 0.0107 |
| 3156 | HMGCR | HCC2 | Human | Liver | HCC | 1.34e-11 | 3.29e+00 | 0.5341 |
| 3156 | HMGCR | Pt14.a | Human | Liver | HCC | 1.77e-04 | 4.16e-01 | 0.0169 |
| 3156 | HMGCR | S014 | Human | Liver | HCC | 3.95e-12 | 6.94e-01 | 0.2254 |
| 3156 | HMGCR | S015 | Human | Liver | HCC | 5.89e-13 | 8.32e-01 | 0.2375 |
| 3156 | HMGCR | S016 | Human | Liver | HCC | 2.45e-16 | 7.68e-01 | 0.2243 |
| 3156 | HMGCR | S027 | Human | Liver | HCC | 2.56e-04 | 5.96e-01 | 0.2446 |
| 3156 | HMGCR | S028 | Human | Liver | HCC | 1.01e-13 | 7.60e-01 | 0.2503 |
| 3156 | HMGCR | S029 | Human | Liver | HCC | 6.06e-23 | 1.06e+00 | 0.2581 |
| 3156 | HMGCR | C04 | Human | Oral cavity | OSCC | 4.14e-08 | 4.10e-01 | 0.2633 |
| 3156 | HMGCR | C21 | Human | Oral cavity | OSCC | 1.13e-13 | 5.48e-01 | 0.2678 |
| 3156 | HMGCR | C30 | Human | Oral cavity | OSCC | 2.38e-13 | 6.92e-01 | 0.3055 |
| 3156 | HMGCR | C38 | Human | Oral cavity | OSCC | 2.25e-08 | 1.02e+00 | 0.172 |
| 3156 | HMGCR | C43 | Human | Oral cavity | OSCC | 5.72e-09 | 2.58e-01 | 0.1704 |
| 3156 | HMGCR | C57 | Human | Oral cavity | OSCC | 2.77e-04 | 2.61e-01 | 0.1679 |
| 3156 | HMGCR | SYSMH1 | Human | Oral cavity | OSCC | 3.50e-02 | 1.24e-01 | 0.1127 |
| 3156 | HMGCR | SYSMH2 | Human | Oral cavity | OSCC | 3.32e-03 | 1.48e-01 | 0.2326 |
| 3156 | HMGCR | SYSMH3 | Human | Oral cavity | OSCC | 1.56e-14 | 4.30e-01 | 0.2442 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
| GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
| GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
| GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
| GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
| GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
| GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
| GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
| GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
| GO:0042177 | Colorectum | AD | negative regulation of protein catabolic process | 55/3918 | 121/18723 | 1.19e-09 | 8.85e-08 | 55 |
| GO:0009743 | Colorectum | AD | response to carbohydrate | 86/3918 | 253/18723 | 8.43e-07 | 2.90e-05 | 86 |
| GO:0042060 | Colorectum | AD | wound healing | 128/3918 | 422/18723 | 2.73e-06 | 7.89e-05 | 128 |
| GO:0034284 | Colorectum | AD | response to monosaccharide | 76/3918 | 225/18723 | 4.64e-06 | 1.23e-04 | 76 |
| GO:0033500 | Colorectum | AD | carbohydrate homeostasis | 84/3918 | 259/18723 | 9.10e-06 | 2.15e-04 | 84 |
| GO:0009746 | Colorectum | AD | response to hexose | 73/3918 | 219/18723 | 1.20e-05 | 2.65e-04 | 73 |
| GO:0031667 | Colorectum | AD | response to nutrient levels | 138/3918 | 474/18723 | 1.22e-05 | 2.68e-04 | 138 |
| GO:0010563 | Colorectum | AD | negative regulation of phosphorus metabolic process | 130/3918 | 442/18723 | 1.26e-05 | 2.76e-04 | 130 |
| GO:0009749 | Colorectum | AD | response to glucose | 71/3918 | 212/18723 | 1.31e-05 | 2.85e-04 | 71 |
| GO:0042593 | Colorectum | AD | glucose homeostasis | 83/3918 | 258/18723 | 1.44e-05 | 3.11e-04 | 83 |
| GO:0001678 | Colorectum | AD | cellular glucose homeostasis | 60/3918 | 172/18723 | 1.49e-05 | 3.18e-04 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
| hsa041521 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
| hsa041522 | Colorectum | MSS | AMPK signaling pathway | 41/1875 | 121/8465 | 1.91e-03 | 9.83e-03 | 6.03e-03 | 41 |
| hsa041523 | Colorectum | MSS | AMPK signaling pathway | 41/1875 | 121/8465 | 1.91e-03 | 9.83e-03 | 6.03e-03 | 41 |
| hsa041524 | Colorectum | FAP | AMPK signaling pathway | 37/1404 | 121/8465 | 8.97e-05 | 8.56e-04 | 5.21e-04 | 37 |
| hsa04976 | Colorectum | FAP | Bile secretion | 24/1404 | 89/8465 | 8.76e-03 | 3.21e-02 | 1.96e-02 | 24 |
| hsa041525 | Colorectum | FAP | AMPK signaling pathway | 37/1404 | 121/8465 | 8.97e-05 | 8.56e-04 | 5.21e-04 | 37 |
| hsa049761 | Colorectum | FAP | Bile secretion | 24/1404 | 89/8465 | 8.76e-03 | 3.21e-02 | 1.96e-02 | 24 |
| hsa041526 | Colorectum | CRC | AMPK signaling pathway | 31/1091 | 121/8465 | 1.04e-04 | 1.57e-03 | 1.07e-03 | 31 |
| hsa041527 | Colorectum | CRC | AMPK signaling pathway | 31/1091 | 121/8465 | 1.04e-04 | 1.57e-03 | 1.07e-03 | 31 |
| hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa009005 | Esophagus | ESCC | Terpenoid backbone biosynthesis | 20/4205 | 23/8465 | 2.14e-04 | 7.87e-04 | 4.03e-04 | 20 |
| hsa0415213 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa0090012 | Esophagus | ESCC | Terpenoid backbone biosynthesis | 20/4205 | 23/8465 | 2.14e-04 | 7.87e-04 | 4.03e-04 | 20 |
| hsa0415241 | Liver | HCC | AMPK signaling pathway | 77/4020 | 121/8465 | 2.32e-04 | 1.11e-03 | 6.18e-04 | 77 |
| hsa00900 | Liver | HCC | Terpenoid backbone biosynthesis | 17/4020 | 23/8465 | 9.26e-03 | 2.46e-02 | 1.37e-02 | 17 |
| hsa0415251 | Liver | HCC | AMPK signaling pathway | 77/4020 | 121/8465 | 2.32e-04 | 1.11e-03 | 6.18e-04 | 77 |
| hsa009001 | Liver | HCC | Terpenoid backbone biosynthesis | 17/4020 | 23/8465 | 9.26e-03 | 2.46e-02 | 1.37e-02 | 17 |
| hsa009004 | Oral cavity | OSCC | Terpenoid backbone biosynthesis | 19/3704 | 23/8465 | 1.55e-04 | 5.34e-04 | 2.72e-04 | 19 |
| hsa041529 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HMGCR | SNV | Missense_Mutation | rs144482710 | c.1062N>G | p.Ile354Met | p.I354M | P04035 | protein_coding | tolerated(0.15) | benign(0.03) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| HMGCR | SNV | Missense_Mutation | novel | c.1297N>A | p.Glu433Lys | p.E433K | P04035 | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HMGCR | SNV | Missense_Mutation | c.2184N>C | p.Met728Ile | p.M728I | P04035 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HMGCR | SNV | Missense_Mutation | novel | c.2537N>C | p.Val846Ala | p.V846A | P04035 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HMGCR | SNV | Missense_Mutation | rs777178244 | c.746C>T | p.Pro249Leu | p.P249L | P04035 | protein_coding | deleterious(0.03) | probably_damaging(0.986) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HMGCR | SNV | Missense_Mutation | novel | c.1380A>T | p.Lys460Asn | p.K460N | P04035 | protein_coding | tolerated(0.54) | benign(0.01) | TCGA-E2-A3DX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| HMGCR | SNV | Missense_Mutation | c.761N>T | p.Gln254Leu | p.Q254L | P04035 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| HMGCR | SNV | Missense_Mutation | c.762N>C | p.Gln254His | p.Q254H | P04035 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| HMGCR | SNV | Missense_Mutation | c.1922G>A | p.Arg641His | p.R641H | P04035 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| HMGCR | SNV | Missense_Mutation | c.109T>C | p.Phe37Leu | p.F37L | P04035 | protein_coding | tolerated(0.7) | benign(0.001) | TCGA-3L-AA1B-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | inhibitor | 135649749 | ||
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | Sterol derivative 1 | |||
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | CRILVASTATIN | CRILVASTATIN | ||
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | Crestor/TriLipix | |||
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | inhibitor | 249565672 | ||
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | inhibitor | 135652701 | LOVASTATIN | |
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | SIMVASTATIN | SIMVASTATIN | ||
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | inhibitor | 135649752 | ||
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL393220 | ATORVASTATIN CALCIUM | |
| 3156 | HMGCR | ENZYME, DRUGGABLE GENOME | FLUVASTATIN | FLUVASTATIN |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |